Silence Therapeutics stock closed at $19.58 on October 19, 2026, up 125.58% after Merck KGaA, Darmstadt, Germany agreed to acquire the biotechnology company for $20 per American depositary share in cash. The proposed transaction values Silence’s equity at approximately $1.3 billion, but payment remains conditional on shareholder, court and regulatory approvals.
Key Takeaways
- The October 19 close was 42 cents below the agreed $20-per-ADS cash consideration.
- The buyer is Germany’s Merck KGaA, not the US drugmaker Merck & Co.
- The companies expect completion in the first quarter of 2027, subject to outstanding approvals.
Table of Contents
- Silence Therapeutics stock trades below the cash offer
- Shareholder and court approvals remain outstanding
- Divesiran is central to the pipeline rationale
- Conclusion
Silence Therapeutics stock trades below the cash offer
The ADSs gained $10.90 from their October 16 close of $8.68. Most of that repricing occurred before regular trading began: the October 19 session opened at $19.585 and stayed within a narrow range of $19.56 to $19.61.
Silence’s acquisition announcement sets the consideration at $20 per ADS, payable upon completion. Each ADS represents three ordinary shares. The agreement was signed on October 18 and announced the following day.
The 42-cent difference between the closing price and the agreed payment represents about 2.15% of the closing price. That is a conditional gross spread, not a guaranteed return: the acquisition has not closed, and holders face the risk of delay or failure.
The stock’s 125.58% gain and the company’s stated 130% offer premium measure different things. The first compares the October 19 market close with the previous close; the second compares the higher cash consideration with that same pre-announcement price.
| Item | Details |
|---|---|
| Cash per ordinary share | $6.6667 |
| Enterprise value | Approximately $1.1 billion |
| Premium to 30-day volume-weighted average price | 82% above $10.99 |
| October 19 trading volume | 71,918,760 ADSs |
Shareholder and court approvals remain outstanding
The acquisition is structured as a UK scheme of arrangement under Part 26 of the Companies Act 2006. Silence’s board unanimously approved the transaction, and securityholders representing approximately 14% of voting power signed support agreements. Those commitments do not replace the required shareholder votes.
The scheme requires approval by a majority in number representing at least 75% in value of shareholders present and voting at the scheme meeting. A related special resolution also requires at least 75% of voting rights cast. Further conditions include High Court sanction, US antitrust waiting-period requirements and German antitrust approval or deemed approval.
There is no financing condition. The agreement sets an outside date of 11:59 p.m. London time on April 30, 2027, subject to a limited five-business-day extension tied to court sanction. Silence may owe Merck KGaA a $13 million termination fee in specified circumstances; that fee is not compensation payable to ADS holders.
Divesiran is central to the pipeline rationale
The transaction would bring Silence’s experimental siRNA medicines into Merck KGaA, including divesiran for polycythemia vera, a rare blood cancer. Merck KGaA chief executive Kai Beckmann said the planned acquisition would strengthen the company’s capabilities in specialty and rare diseases.
Silence’s August 10, 2026 clinical update reported an 88% response rate for divesiran versus 19% for placebo in a 48-patient Phase 2 study. Response meant avoiding phlebotomy while maintaining hematocrit below 45% during weeks 18 through 36.
A Phase 3 trial of quarterly dosing was anticipated in the first half of 2027. That remains a development plan, not a trial already under way or a regulatory approval.
Conclusion
The next formal step to watch is Silence’s planned proxy statement and scheme documentation, which will set out the shareholder approval process. Until the scheme becomes effective, the $20-per-ADS consideration remains an agreed payment subject to closing conditions.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
